NCT06170489 2025-02-28
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting